What we do

To achieve our goals, we create open and inclusive platforms where early career professionals can connect with world-leading experts in Pulmonary Hypertension (PH). Through these platforms, we share research and collaborate on new ideas. We bridge the divide between low, middle, and high-income countries to share knowledge and understanding on a global level. Our platforms include:

Annual Congress

Our Annual Congresses are pivotal gatherings for experts in Pulmonary Vascular Disease (PVD), offering a dynamic platform for interdisciplinary dialogue and innovation. They are run annually in different countries around the world. 

Our previous 16 Congresses have been held in London, UK (2024), Athens, Greece (2022), Lima, Peru (2020), Barcelona, Spain (2019), Singapore (2018), Miami, USA  (2017), Rome, Italy (2016), Guangzhou, China (2015), Giessen, Germany (2014), Istanbul, Turkey (2013), Cape Town, South Africa (2012), Panama City, Panama (2011), Lisbon, Portugal (2010), Mexico City, Mexico (2009), Marbella, Spain (2008), and Malta (2007). 

Through keynote lectures, scientific presentations, and networking sessions, attendees collaborate on cutting-edge research and emerging therapies, ultimately aiming to improve patient care and outcomes globally. These congresses play a crucial role in fostering international collaboration, translating research into practice, and advocating for greater awareness and resources in the field.

PVRI 2025 Rio

Drug Discovery and Development Symposium

Our annual Drug Discovery and Development Symposium is held in June/July, alternating in location between USA and Europe. The event provides a dedicated platform for regulatory, industry & academic bodies to meet network and advance shared research on drug development in pulmonary hypertension.


PVRI 2024 Digital

We host monthly webinars with keynote talks from senior experts in the field of PH as well as young investigators. Each session offers ample time for discussion to encourage active participation and debate. They take place on the second Wednesday of each month at 15:00 BST/GMT.

Our PVRI Digital series was born in January 2021 amidst the Covid 19 pandemic, when our face-to-face meetings had to be postponed. Since then, we’ve hosted regular monthly webinars and reached hundreds of people. In addition to our in-person meetings and symposia, this series enables us to connect with our worldwide community to continue to explore and discuss important new research. 

The current series, PVRI 2024 Digital, has been developed by Patricia Thistlethwaite MD, PhD, University of California San Diego and takes place on the second Wednesday of each month at 15:00 BST/GMT. They feature keynote talks from senior experts in the field of PH as well as young investigators. Each session offers ample time for discussion to encourage active participation and debate. 

PVRI 2024 Digital 

Community Calls

Our Community Calls take place monthly, and are an informal discussion on the latest news and advancements in PH. Our hosts invite guest authors to the call, and everyone in the PH community is invited to join the discussion. The calls attract a diverse audience, on average 58 participants from across 18 countries, and usually take place on the last Thursday of every month. Calls are recorded and hosted on our website.

Meet our Community Call Hosts

Katrina Barry

Katrina Barry, MPH, is a patient advocate for Pulmonary Hypertension. Katrina studied biology at Boston University and then worked in personalized medicine research at Brigham and Women’s Hospital in Boston, MA, USA. Katrina was later diagnosed with pulmonary hypertension. She has master’s in public health, with a concentration in monitoring and evaluation of global health programs and a context certificate in infectious disease. Her research interests are focused on the global burden of pulmonary hypertension and how to manage the disease in low-resource settings. Her background in medical research led her to work in patient advocacy, helping patients navigate the devastation of the disease and the complexity of clinical trials. Katrina is a volunteer patient consultant for Merck Pharmaceuticals and runs the unofficial Facebook page for Sotatercept/Winrevair. Katrina has been a moderator with PVRI since 2022.

Joel James

Dr Joel James is a cell signaling enthusiast and a K99/R00 postdoctoral fellow at Indiana University, Indianapolis. He has a PhD in Biochemistry, with a specialized focus on mitochondrial redox biology. His current interests are mitochondrial dysfunction and cell-cell communication in Pulmonary Hypertension. Joel's latest research delves into the intricate world of endothelial cell heterogeneity and pericyte function, contributing to our understanding of pulmonary hypertension.

Tatiana Kudryashova

Dr Kudryashova is an Assistant Professor at University of Pittsburgh, School of Medicine. Her research interests are focused on investigation of molecular and cellular mechanisms of pulmonary arterial hypertension (PAH), especially mechanisms of pulmonary vascular remodeling. Dr Kudryashova's long-standing research interests are focused on investigating sex-specific mechanisms of pulmonary vascular remodeling and role of extracellular matrix in PAH and development of therapeutic treatment, which can attenuate pulmonary vascular remodeling in PAH.

Lucilla Piccari

Dr Lucilla Piccari, M.D., Ph.D. is a pulmonologist at the Pulmonary Hypertension nit in Hospital del Mar (Barcelona, Spain), where she coordinates the Spanish Registry of Pulmonary Hypertension in Lung Disease (Registro Español de Hipertensión pulmonar Asociada a enfermedad Respiratoria, REHAR). She is the Director of the Pulmonary Vascular Research Program at the Spanish Pulmonology and Thoracic Surgery Society (SEPAR). Her research interests are focused on phenotyping in Group 3 pulmonary hypertension, the patient perspective in pulmonary hypertension and the effects of climate change and social determinants of health on pulmonary vascular disease.

Sandeep Sahay

Dr Sahay is a dedicated pulmonary critical care physician with specialization in pulmonary vascular diseases. Currently he is an associate professor in the division of pulmonary, critical care and sleep Medicine, at the Houston Methodist Hospital. He also serves as co-director of the pulmonary hypertension program at the Houston Methodist Hospital. He is well known for his work in the field of pulmonary hypertension. With a passion for improving patient outcomes, he focuses his research on risk stratification in pulmonary hypertension, PH ILD and CTEPH. As a national leader in the space, he serves as Principal investigator on many phase 2 and 3 clinical trials investigating newer therapies for the treatment of pulmonary arterial hypertension. Attributed to his sharp knowledge and skill, he is invited to participate in many scientific steering committees, national leadership roles, guideline panels and in decision making roles with industry and regulatory leadership. He is the Chair of the American college of chest physician, CHEST’s Pulmonary Vascular diseases section. He has history of working with the CHEST organization for a long time. He started as a fellow in training in the PVD network in 2013. Owing to his active contribution to the CHEST society, he is now the Chair of the same PVD section. He was awarded ACCP CHEST PAH research grant in 2017 to assess the role of estrogen in portopulmonary hypertension as a mentee. After successfully completing his research, he mentored his fellow to receive the ILD research grant award with ACCP CHEST in 2020. Additionally, he also serves executive committee of the American Thoracic Society’s pulmonary circulation assembly and Pulmonary Hypertension association’s scientific leadership committee. He has published numerous scientific papers related to pulmonary hypertension. He also serves as Associate Editor of pulmonary circulation, JHLT Open and Respiratory Medicine Journals. He routinely gets invited to speak in national and international scientific meetings. He serves on end point adjudication committees, DSMB’s for NIH funded studies and multiple clinical trials. He enjoys teaching and learning from the Methodist faculty and fellows as well as medical colleagues around the world and enjoys working with house staff and students at the Methodist. Taking care of PH patients is the most gratifying experience for him. He has demonstrated his passion in improving lives of patients with advanced lung diseases like PH and ILD. Outside interests includes listening to music, traveling and spending time with family.

Jason Weatherald

Dr Jason Weatherald is an Associate Professor at the University of Alberta, specialising in pulmonary arterial hypertension and acute pulmonary embolism research. His work focuses on risk assessment methods and patient-oriented studies in pulmonary hypertension, including innovative clinical trial endpoints and designs. 

Since 2020, Dr Weatherald has also contributed significantly to COVID-19 research, investigating awake-prone positioning and dyspnea mechanisms in Long Covid. Alongside his clinical interests in pulmonary hypertension, he demonstrates expertise in lung transplantation and thromboembolic disease. Recognised in numerous publications, Dr Weatherald is a leading figure driving advancements in pulmonary medicine, with a commitment to improving patient care and reshaping clinical practice. 

Our Task Forces and IDDI Workstreams 

Our Regional and Disease Specialty Task Forces are active worldwide, raising awareness of pulmonary vascular disease and addressing key challenges in its causes, effects, and treatment. Our Innovative Drug Development Initiative (IDDI) Workstreams find practical solutions to the key challenges facing pulmonary hypertension physicians, academics, industry, and regulators. 

IDDI Workstreams and Task Forces